🔓 Unlock the full profile of Adi Eldar-Lissai (Fulcrum Therapeutics), including verified contact details, financial insights, and professional associations.
See Adi Eldar-Lissai Full ProfileBelow are the ✅ Verified Contact Details to help you connect directly:
Email: adi*****@ful******.com
Mobile: 83146*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- Adi Eldar-Lissai is the Founder of Fulcrum Therapeutics, which was established in 2016 and is publicly traded on NASDAQ under the symbol FULC.
- Under the leadership of Adi Eldar-Lissai, Fulcrum Therapeutics has focused on developing therapies for genetically defined diseases, significantly contributing to the healthcare landscape.
- Adi Eldar-Lissai currently serves as a member of the Board of Advisors at Envoya Inc., starting from January 2025, broadening the influence and contributions in the biotech industry.
- In May 2024, Adi Eldar-Lissai is set to take on a role as a Board Member at the Museum of Science, reflecting a commitment to education and community engagement.
- Prior to founding Fulcrum Therapeutics, Adi served as the Executive Director of Medical Affairs, Health Economics & Outcomes Research at Fulcrum, overseeing critical initiatives until February 2024.
- Experience includes a pivotal role at Sage Therapeutics, where Adi worked through various titles from Senior Director to Associate Director, primarily focused on Health Economics and Outcomes Research between 2017 and 2022.
- Adi has also contributed as an Associate Director in Global Market Access at Biogen, showcasing an extensive background in market access and health economics.
- Career beginnings included a Research Fellow position at the Finger Lakes Health Systems Agency, laying the groundwork for a focus on research and health outcomes.